Literature DB >> 20599746

AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival.

Jennifer Woodard1, Leonidas C Platanias.   

Abstract

Extensive studies over the years have shown that the AMP-activated kinase (AMPK) exhibits negative regulatory effects on the activation of the mammalian target of rapamycin (mTOR) signaling cascade. We examined the potential involvement of AMPK in the regulation of growth and survival of malignant melanoma cells. In studies using the AMPK activators AICAR or metformin, we found potent inhibitory effects of AMPK activity on the growth of SK-MEL-2 and SK-MEL-28 malignant melanoma cells. Induction of AMPK activity was also associated with inhibition of the ability of melanoma cells to form colonies in an anchorage-independent manner in soft agar, suggesting an important role of the pathway in the control of malignant melanoma tumorigenesis. Furthermore, AICAR-treatment resulted in malignant melanoma cell death and such induction of apoptosis was further enhanced by concomitant statin-treatment. Taken together, our results provide evidence for potent inhibitory effects of AMPK on malignant melanoma cell growth and survival and raise the potential of AMPK manipulation as a novel future approach for the treatment of malignant melanoma. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599746      PMCID: PMC2927205          DOI: 10.1016/j.bbrc.2010.06.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  AMP-activated protein kinase: the energy charge hypothesis revisited.

Authors:  D G Hardie; S A Hawley
Journal:  Bioessays       Date:  2001-12       Impact factor: 4.345

2.  Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype.

Authors:  Johannes V Swinnen; Annelies Beckers; Koen Brusselmans; Sophie Organe; Joanna Segers; Leen Timmermans; Frank Vanderhoydonc; Ludo Deboel; Rita Derua; Etienne Waelkens; Ellen De Schrijver; Tine Van de Sande; Agnès Noël; Fabienne Foufelle; Guido Verhoeven
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

Review 3.  The AMP-activated protein kinase pathway--new players upstream and downstream.

Authors:  D Grahame Hardie
Journal:  J Cell Sci       Date:  2004-11-01       Impact factor: 5.285

4.  Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.

Authors:  Tobias Sinnberg; Konstantinos Lasithiotakis; Heike Niessner; Birgit Schittek; Keith T Flaherty; Dagmar Kulms; Evelyn Maczey; Minia Campos; Jeannette Gogel; Claus Garbe; Friedegund Meier
Journal:  J Invest Dermatol       Date:  2008-12-11       Impact factor: 8.551

5.  Role of AMP-activated protein kinase in mechanism of metformin action.

Authors:  G Zhou; R Myers; Y Li; Y Chen; X Shen; J Fenyk-Melody; M Wu; J Ventre; T Doebber; N Fujii; N Musi; M F Hirshman; L J Goodyear; D E Moller
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms.

Authors:  Xiaoqin Xiang; Asish K Saha; Rong Wen; Neil B Ruderman; Zhijun Luo
Journal:  Biochem Biophys Res Commun       Date:  2004-08-13       Impact factor: 3.575

Review 7.  Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status.

Authors:  D Grahame Hardie
Journal:  Endocrinology       Date:  2003-09-04       Impact factor: 4.736

Review 8.  Treatment of metastatic melanoma: an overview.

Authors:  Shailender Bhatia; Scott S Tykodi; John A Thompson
Journal:  Oncology (Williston Park)       Date:  2009-05       Impact factor: 2.990

9.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?

Authors:  J M Corton; J G Gillespie; S A Hawley; D G Hardie
Journal:  Eur J Biochem       Date:  1995-04-15

10.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.

Authors:  Reuben J Shaw; Monica Kosmatka; Nabeel Bardeesy; Rebecca L Hurley; Lee A Witters; Ronald A DePinho; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-25       Impact factor: 11.205

View more
  25 in total

1.  A phase I study of temsirolimus and metformin in advanced solid tumours.

Authors:  Mary J MacKenzie; Scott Ernst; Craig Johnson; Eric Winquist
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

Review 2.  Metformin and cancer.

Authors:  Natalia G Vallianou; Angelos Evangelopoulos; Christos Kazazis
Journal:  Rev Diabet Stud       Date:  2014-02-10

3.  Inhibition of melanogenesis by the antidiabetic metformin.

Authors:  Abdelali Lehraiki; Patricia Abbe; Michael Cerezo; Florian Rouaud; Claire Regazzetti; Bérengère Chignon-Sicard; Thierry Passeron; Corine Bertolotto; Robert Ballotti; Stéphane Rocchi
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

4.  Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes.

Authors:  Wang Chen-Pin; Hernandez Javier; Carlos Lorenzo; John R Downs; Ian M Thompson; Bradley Pollock; Donna Lehman
Journal:  Ann Transl Med Epidemiol       Date:  2014

5.  Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.

Authors:  M R Danzig; S Kotamarti; R A Ghandour; M B Rothberg; B P Dubow; M C Benson; K K Badani; J M McKiernan
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-18       Impact factor: 5.554

6.  Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration.

Authors:  Guanzhao Liang; Minglei Ding; Haitao Lu; N A Cao; Yandong Niu; Yang Gao; Jie Lu
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

7.  Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

Authors:  Jessica A Fowler; Seint T Lwin; Matthew T Drake; James R Edwards; Robert A Kyle; Gregory R Mundy; Claire M Edwards
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

8.  Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.

Authors:  Eliza Vakana; Jessica K Altman; Heather Glaser; Nicholas J Donato; Leonidas C Platanias
Journal:  Blood       Date:  2011-10-21       Impact factor: 22.113

9.  Involvement of ER stress and activation of apoptotic pathways in fisetin induced cytotoxicity in human melanoma.

Authors:  Deeba N Syed; Rahul K Lall; Jean Christopher Chamcheu; Omar Haidar; Hasan Mukhtar
Journal:  Arch Biochem Biophys       Date:  2014-07-09       Impact factor: 4.013

10.  Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.

Authors:  Dinoop Ravindran Menon; Sabrina Hammerlindl; Heinz Hammerlindl; Abdullah Al Emran; Joachim Torrano; Katrin Sproesser; Divya Thakkar; Min Xiao; Victoria G Atkinson; Brian Gabrielli; Nikolas K Haass; Meenhard Herlyn; Clemens Krepler; Helmut Schaider
Journal:  Clin Cancer Res       Date:  2017-12-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.